<div id="readability-page-1"><p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is anticipated to issue its  Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Investors may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 2:00 AM ET.</p><div><p><span></span><span>Get <strong>Bicycle Therapeutics</strong> alerts:</span></p></div><h2>Bicycle Therapeutics Stock Performance</h2><p>Shares of BCYC opened at $5.24 on Tuesday. The company has a market capitalization of $363.50 million, a PE ratio of -1.45 and a beta of 1.63. The company's 50 day moving average price is $6.60 and its 200 day moving average price is $7.10. Bicycle Therapeutics has a 52 week low of $5.18 and a 52 week high of $13.11. </p><h2>Insider Activity at Bicycle Therapeutics</h2><p>In related news, CFO Alethia Young sold 4,334 shares of the firm's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at approximately $565,155.69. This trade represents a 4.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin Lee sold 10,989 shares of the business's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the transaction, the chief executive officer directly owned 618,996 shares of the company's stock, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 38,029 shares of company stock valued at $251,966. Corporate insiders own  8.50% of the company's stock. </p><h2>Hedge Funds Weigh In On Bicycle Therapeutics</h2><p>A number of institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group bought a new stake in  Bicycle Therapeutics during the 4th quarter valued at approximately $69,000.  Ausdal Financial Partners Inc. acquired a new stake in shares of  Bicycle Therapeutics in the second quarter worth $70,000.  Vontobel Holding Ltd. bought a new position in  Bicycle Therapeutics during the fourth quarter worth $71,000.  Sei Investments Co. acquired a new position in  Bicycle Therapeutics during the 2nd quarter valued at $74,000.  Finally, Ameriprise Financial Inc. bought a new stake in  Bicycle Therapeutics in the 2nd quarter valued at $86,000. 86.15% of the stock is currently owned by institutional investors. </p><h2>Analyst Ratings Changes</h2><p>A number of equities analysts have recently weighed in on BCYC shares. Royal Bank Of Canada  reaffirmed a &#34;sector perform&#34; rating and issued a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They set a &#34;hold&#34; rating and a $10.00 price target for the company. Citigroup  reissued an &#34;outperform&#34; rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, JMP Securities  set a $12.00 price objective on Bicycle Therapeutics in a report on Friday, October 31st. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $20.20.</p><p><b>Get Our Latest Stock Report on BCYC</b></p><h2>Bicycle Therapeutics Company Profile</h2> (Get Free Report)<p>Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.  </p><p>Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Bicycle Therapeutics</li><li>Your Bank Account Is No Longer Safe</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>This $15 Stock Could Go Down as the #1 Stock of 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

BCYC

BTTX

<p>Bicycle Therapeutics (NASDAQ:BCYC) is set to release its Q4 2025 earnings on February 24, with analysts expecting a loss of $1.00 per share. The company's stock opened at $5.24, with a market cap of $363.50 million. Recent insider sales include CFO Alethia Young and CEO Kevin Lee, who sold shares at prices around $6.49 and $6.46, respectively. Institutional investors hold 86.15% of the stock, and analysts have a consensus rating of "Moderate Buy" with a price target of $20.20.</p>

Bicycle Therapeutics (BCYC) Projected to Post Quarterly Earnings on Tuesday